Publications by authors named "Chiara Borin"
Background: Mitotane is the only drug approved for the treatment of adrenocortical carcinoma (ACC). Although it has been used for many years, its mechanism of action remains elusive. H295R cells are, in ACC, an essential tool to evaluate drug mechanisms, although they often lead to conflicting results.
View Article and Find Full Text PDFObjective: The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences.
Design And Methods: Retrospective analysis in a single reference center of 106 patients with ACC recurrence.
Results: The median follow-up was 45 months, the median recurrence-free survival (RFS) 12 months (IQR 6-23), and the median overall survival (OS) 45 months (IQR 29-75).
Article Synopsis
- The study investigates how mitotane treatment affects lipid profiles differently in male and female patients after surgery for adrenocortical carcinoma.
- Results show that higher mitotane concentrations lead to increased levels of HDL, total cholesterol, triglycerides, and LDL, with variations observed between genders and pre- vs. post-menopausal women.
- The research emphasizes the importance of considering sex differences in treatment, suggesting that a personalized approach may help manage lipid profile changes during mitotane therapy.